Adult Still's disease: New horizons by E. L. Nasonov, E. Feist

Get full text

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) by E. L. Nasonov, E. Feist

Get full text

Sea-level rise drives changes in salinisation patterns in low-lying Bangladesh by Sean E. Feist, Mohammad A. Hoque, Md. Atikul Islam, Ashraf Dewan, Mike Fowler

Get full text

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor in... by E. Feist, S. Fatenejad, S. Grishin, E. Korneva, M.E. Luggen, E. Nasonov, M. Samsonov, J.S. Smolen, R.M. Fleischmann

Get full text

Mapping the value of commercial fishing and potential costs of offshore wind energy on the U.S: West Coast: Towards an assessment of resource use tradeoffs. by Blake E Feist, Robert Griffin, Jameal F Samhouri, Leena Riekkola, Andrew O Shelton, Y Allen Chen, Kayleigh Somers, Kelly Andrews, Owen R Liu, Jennifer Ise

Get full text

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab) by A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov

Get full text